Vaccinating the world’s population quickly in a pandemic has enormous health and economic benefits. We analyze the problem faced by governments in determining the scale and structure of procurement for vaccines. We analyze alternative approaches to procurement, arguing that buyers should directly fund manufacturing capacity and shoulder most of the risk of failure, while maintaining some direct incentives for speed. We analyzed the optimal portfolio of vaccine investments for countries with different characteristics as well as the implications for international cooperation. Our analysis, considered in light of the experience of 2020, suggests lessons for future pandemics. 

More on this topic

BFI Working Paper·Jun 5, 2025

Administrative Fragmentation in Health Care

Riley League and Maggie Shi
Topics: Health care
BFI Working Paper·May 13, 2025

Saved by Medicaid: New Evidence on Health Insurance and Mortality from the Universe of Low-Income Adults

Angela Wyse and Bruce Meyer
Topics: Health care, Tax & Budget
BFI Working Paper·Apr 28, 2025

Screening Through Soft Spending Limits: Evidence from the Medicare Therapy Cap

Ashvin Gandhi and Maggie Shi
Topics: Health care